Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | ARAF | P10398 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13183226 | 0.83 | MEN1 (0.40) | NR4A1PPARGEGFRHDAC1ALDH1A1 | |
| SCHEMBL13211386 | 0.81 | NR4A1 (0.54) | NR4A1SMN1; SMN2RAF1ARAFBRAF | |
| SCHEMBL502859 | 0.81 | NQO2 (0.38) | NR4A1PPARGSMN1; SMN2ALDH1A1GCK | |
| SCHEMBL2028918 | 0.79 | LOX (0.41) | LOXLOXL2NOS3NOS1NOS2 | |
| SCHEMBL3177144 | 0.79 | SMN1; SMN2 (0.54) | LOXLOXL2NOS3NOS1NOS2 | |
| SCHEMBL502649 | 0.78 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL1131363 | 0.76 | ALDH1A1 (0.53) | NOS3NOS1NOS2NR4A1SMN1; SMN2 | |
| SCHEMBL12355368 | 0.76 | KDR (0.58) | RAF1BRAF | |
| SCHEMBL23795587 | 0.75 | MAPK14 (0.50) | BRAFGCK | |
| SCHEMBL30313600 | 0.75 | MAPK14 (0.50) | BRAFGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404918-B1 | PYRIDINE DERIVATIVE AS PPARY INHIBITOR | DAIICHI SANKYO CO LTD (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-8946264-B2 | Pyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20130045994-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-21 | — | — | US | disclosed |
| US-20120029026-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2404918-A1 | PYRIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010101164-A1 | PYRIDINE DERIVATIVE | 第一三共株式会社 (JP) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029026-A1 | PYRIDINE DERIVATIVE | PPARD, PPARG, PPARA | LOX 2756/4885LOXL2 4525/4885NOS3 2910/4885 |
| US-20130045994-A1 | PYRIDINE DERIVATIVE | PPARD, PPARG, PPARA | LOX 2756/4885LOXL2 4525/4885NOS3 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.